<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630939</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-114-101</org_study_id>
    <nct_id>NCT03630939</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Vehicle-Controlled Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 Gel in Subjects With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Escalier Biosciences B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovaderm Research Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Escalier Biosciences B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group
      proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and
      preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for
      42 days (6 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Lesion Severity Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline in Total Lesion Severity Score (sum of scores for Induration, Erythema, &amp; Desquamation; score range: 0-12; lower score is better outcome) at Week 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clear or almost clear on the Physician Global Assessment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of subjects with clear or almost clear on the Physician Global Assessment (PGA) at Week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with PASI75</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of subjects with PASI75 at Week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in erythema score over time</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline in erythema score (score range: 0-4; lower score is better outcome) at Weeks 1, 2, 4, and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in induration score over time</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline in induration score (score range: 0-4; lower score is better outcome) at Weeks 1, 2, 4, and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in desquamation score over time</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline in desquamation score (score range: 0-4; lower score is better outcome) at Weeks 1, 2, 4, and 6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Psoriatic Plaque</condition>
  <arm_group>
    <arm_group_label>ESR-114 1.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESR-114 1.5% Topical Gel BID for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESR-114 5.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESR-114 5.0% Topical Gel BID for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Topical Gel BID for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESR-114</intervention_name>
    <description>ESR-114 Topical Gel</description>
    <arm_group_label>ESR-114 1.5%</arm_group_label>
    <arm_group_label>ESR-114 5.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Topical Gel</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a history of plaque psoriasis for at least 6 months.

          -  Subject has PGA of mild (2) or moderate (3) at Day 1.

          -  Subject has total LSS of ≥6 at Day 1.

          -  Subjects with plaque psoriasis-affected BSA to be treated of 1% to 15% at Screening
             and Day 1.

        Exclusion Criteria:

          -  Subject has non-plaque psoriasis at Screening and Day 1.

          -  Subject has a history of skin disease or presence of skin condition that, in the
             opinion of the Investigator, would interfere with the study assessments at Screening
             and Day 1.

          -  Subject has used any topical therapy to treat psoriasis within 2 weeks prior to Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison Luo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Escalier Biosciences B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site 19</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 11</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 13</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

